Cipla Ltd said the US Food and Drug Administration (USFDA) has concluded a routine inspection of its wholly owned subsidiary InvaGen Pharmaceuticals Inc.’s manufacturing facility in Hauppauge, Long Island, New York, with zero Form 483 observations.

The current Good Manufacturing Practices (cGMP) inspection was conducted from October 19 to 22, 2026.

Form 483 observations are issued by the USFDA to notify company management of potentially objectionable conditions identified during an inspection.